{"id":"W4401436098","doi":"10.1093/bjd/ljae266.008","title":"624 - Vitiligo biomarker CXCL10 correlates with clinical response in the phase 2 randomized, double-blind, vehicle-controlled TRuE-V mechanism of action study","year":2024,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"melanin and skin pigmentation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Barrie Urology Group; Lynde Centre for Dermatology","funders":"Astellas Pharma; LEO Pharma; Galderma; Incyte; Celgene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Vitiligo; Medicine; Ruxolitinib; Tolerability; Biomarker; Internal medicine; Randomized controlled trial; Clinical trial; Dermatology; Gastroenterology; Oncology; Adverse effect; Myelofibrosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002182202,0.001372918,0.00222264,0.0003673667,0.0003122971,0.0009858673,0.0008382329,0.001492068,0.007244566],"category_scores_gemma":[0.001134791,0.0006785266,0.001292526,0.00027828,0.0007190949,0.0008833648,0.0003314021,0.001541665,0.001182534],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005898873,"about_ca_system_score_gemma":0.0009324223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002679977,"about_ca_topic_score_gemma":0.0006586121,"domain_scores_codex":[0.9992084,0.000363854,0.00004318523,0.000177128,0.00008416953,0.0001231603],"domain_scores_gemma":[0.9992476,0.0001354091,0.0002430197,0.00007167683,0.00008137859,0.0002209822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9178337,0.02831618,0.002952847,0.0008678453,0.0008476301,0.00005560235,0.00005284002,0.0004339085,0.02300743,0.0001024048,0.001623429,0.02390626],"study_design_scores_gemma":[0.7183295,0.269569,0.00735071,0.00002519218,0.0004608033,0.0000680216,0.00001886086,0.0006816444,0.002389955,0.00009413984,0.0009882126,0.00002382092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854434,0.002377075,0.000925872,0.0003561173,0.0002973078,0.007120353,0.001620997,0.0001674327,0.001691403],"genre_scores_gemma":[0.9867514,0.0008185625,0.001906143,0.0006425296,0.0003562392,0.005522553,0.001096457,0.00002635303,0.002879672],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007244566,"threshold_uncertainty_score":0.02423549,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03642154595813887,"score_gpt":0.3675508723828605,"score_spread":0.3311293264247217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}